Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Advanced Primary HCC Patients
NCT06029829Phase 2Unknown
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in hepatocellular carcinoma (HCC). Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06029829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029829.